Naomi Kouri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5670231/publications.pdf

Version: 2024-02-01

26 papers	6,669 citations	304743 22 h-index	526287 27 g-index
30 all docs	30 docs citations	30 times ranked	10364 citing authors

#	Article	IF	Citations
1	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron, 2011, 72, 245-256.	8.1	4,176
2	Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nature Genetics, 2012, 44, 200-205.	21.4	428
3	Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau). Journal of Molecular Neuroscience, 2011, 45, 384-389.	2.3	295
4	Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nature Reviews Neurology, 2011, 7, 263-272.	10.1	270
5	Brain Expression Genome-Wide Association Study (eGWAS) Identifies Human Disease-Associated Variants. PLoS Genetics, 2012, 8, e1002707.	3.5	225
6	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	12.8	170
7	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimer's Research and Therapy, 2014, 6, 1.	6.2	156
8	Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain, 2011, 134, 3264-3275.	7.6	119
9	Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Medicine, 2018, 15, e1002487.	8.4	111
10	Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathologica, 2017, 133, 825-837.	7.7	90
11	Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum. JAMA Neurology, 2018, 75, 860.	9.0	79
12	Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. Acta Neuropathologica, 2014, 127, 271-282.	7.7	66
13	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathologica, 2018, 136, 389-404.	7.7	59
14	Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Molecular Neurodegeneration, 2018, 13, 37.	10.8	54
15	Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci. Acta Neuropathologica, 2016, 132, 197-211.	7.7	49
16	Altered microRNA expression in frontotemporal lobar degeneration with TDP-43 pathology caused by progranulin mutations. BMC Genomics, 2011, 12, 527.	2.8	48
17	Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy. Acta Neuropathologica, 2018, 136, 709-727.	7.7	47
18	Spectrophotometric determination of aqueous cyanide using a revised phenolphthalin method. Analytica Chimica Acta, 2007, 589, 137-141.	5.4	45

#	Article	IF	Citations
19	Corticobasal degeneration with olivopontocerebellar atrophy and TDP-43 pathology: an unusual clinicopathologic variant of CBD. Acta Neuropathologica, 2013, 125, 741-752.	7.7	40
20	A novel tau mutation, p.K317N, causes globular glial tauopathy. Acta Neuropathologica, 2015, 130, 199-214.	7.7	38
21	Gene expression levels as endophenotypes in genome-wide association studies of Alzheimer disease. Neurology, 2010, 74, 480-486.	1.1	30
22	Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72. Acta Neuropathologica, 2013, 126, 545-554.	7.7	30
23	LRRTM3 Interacts with APP and BACE1 and Has Variants Associating with Late-Onset Alzheimerâ€™s Disease (LOAD). PLoS ONE, 2013, 8, e64164.	2.5	12
24	FTDPâ€17 with Pick bodyâ€like inclusions associated with a novel tau mutation, p.E372G. Brain Pathology, 2017, 27, 612-626.	4.1	11
25	MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features. Acta Neuropathologica Communications, 2020, 8, 218.	5.2	8
26	Latent trait modeling of tau neuropathology in progressive supranuclear palsy. Acta Neuropathologica, 2021, 141, 667-680.	7.7	5